Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P146. Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience
P146. Magnetic resonance imaging evaluation of inflammatory activity in Crohn's disease. A Moroccan monocentric experience
P146. Small bowel Crohn's disease: magnetic resonance can predict with a high accuracy the presence of stenotic lesion. Results of a prospective study
Authors:

S. Pous1, M. Frasson1, M. Aguas1, G. Sanchez1, G. Bastida1, C. Ramirez1, M. Llavador1, E. Garcia-Granero1, P. Nos1, 1La Fe Universitary Hospital, Valencia, Spain

P146

Detection and characterization of colonic dysplastic lesions in IBD surveillance colonoscopy - a randomised comparison of high definition alone with high definition dye spraying and electronic virtual chromoendoscopy using iSCAN

Authors:

M. Iacucci*1, M. Fort Gasia1, S. Urbanski2, P. Minoo2, G. Kaplan1, R. Panaccione1, S. Ghosh1

1University of Calgary, Department of Gastroenterology, Inflammatory Bowel Disease Clinic, Alberta, Canada, 2University of Calgary, Department of Pathology, Calgary, Canada

P147.

Role of endoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis

Authors:

R. Thomas1, P. Kakkadasam Ramaswami2, H. Joshi2, N. Toke2, C. Panackel2, S. Mathai2, 1Medical Trust Hospital, Department of Pathology, Ernakulam, India, 2Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India

P147. Predictors of efficacy, mucosal healing and need for dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary
P147. Risks factors concerning bone loss in Moroccan patients with inflammatory bowel diseases
P147. Serological and genetic markers as predictors of complicated disease in patients with Crohn's disease
Authors:

E. Hoefkens1, M. Ferrante2, F. Princen3, V. Ballet2, I. Cleynen1, P. Rutgeerts2, S. Vermeire2, 1KU Leuven, Department of Clinical and Experimental Medicine, TARGID, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 3Prometheus Laboratories Inc., Research and Development, San Diego, United States

P147

Usefulness of fecal S100A12 in defining mucosal healing in Ulcerative Colitis

Authors:

T. Kobayashi*, O. Takeuchi, S. Kuronuma, M. Nakano, S. Umeda, H. Serizawa, N. Watanabe, T. Hibi

Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

P148.

Role of interferon gamma release assay (IGRA) in differentiating gastrointestinal tuberculosis from Crohn's disease

Authors:

P. Kakkadasam Ramaswami, H. Joshi, N. Toke, C. Panackel, S. Mathai, Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India

P148. Disability in inflammatory bowel disease (IBD): Developing ICF core sets for patients with IBD based on the WHO international classification of functioning, disability and health
P148. Incidence and predictors of colorectal dysplasia and cancer in a population-based cohort of IBD patients in Romania
P148. Screening with holotranscobalamin is superior to serum B12 in identifying vitamin B12 deficiency in patients with Crohn's disease
Authors:

M. Ward1, V. Kariyawasam1, A. Sobczynska-Malefora2, A. Ajaegbu3, J. Sanderson1, D.J. Harrington2, P. Irving1, 1Guy's and St. Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2GSTS Pathology (part of King's Healthcare Partners), The Nutristasis Unit, London, United Kingdom, 3GSTS Pathology (part of King's Healthcare Partners), Diagnostic Haemostasis and Thrombosis, London, United Kingdom

P148

Immunohistochemical staining of plasma cells and eosinophils in Inflammatory Bowel Disease: a preliminary report.

Authors:

G. Canavese*1, V. Villanacci2, R. Rocca3, M. Daperno3, R. Suriani3, M. Salemme2, G. Bassotti4

1Azienda Ospedaliera Città della Salute e della Scienza di Torino, Pathology Department, Torino, Italy, 2Department of Molecular and Translational Medicine, Spedali Civili and University of Brescia, Pathology Section, Brescia, Italy, 3Ospedale Mauriziano, Gastroenterology Department, Torino, Italy, 4Department of Medicine, University of Perugia School of Medicine, Gastroenterology section, Perugia, Italy

P149.

Risk factors for post-colectomy complications in patients with ulcerative colitis

Authors:

Y. Hirayama, T. Ando, K. Ishiguro, O. Maeda, O. Watanabe, K. Morise, K. Maeda, M. Matsushita, K. Furukawa, K. Funasaka, M. Nakamura, R. Miyahara, H. Goto, Nagoya University Graduate School of Medicine, Departmant of Gastroenterology and Hepatology, Nagoya, Japan

P149. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study [Grupo Joven GETECCU]
P149. Pyoderma gangrenosum in adult IBD patients: Prevalence, risk factors and therapeutic control
P149. Screening for preventable infections in IBD patients as per ECCO Consensus Guidance: Is it worth it?
Authors:

S.A. Miller1, L.C. Harrison2, A. Nelson2, K. Ashton2, Y. Houston2, M. Rolph2, S. Sebastian3, 1Hull & York Medical School, United Kingdom, 2Hull & East Yorkshire NHS Trust, United Kingdom, 3Hull & East Yorkshire NHS Trust, Hull & York Medical School, United Kingdom

P149

Clinical Characteristics and Prognosis of Crohn's Disease Patients with Jejunal Involvement in Korea: Results from the CONNECT Study

Authors:

J.K. Jung*1, D.S. Han1, Y. Ro1, C.S. Eun1, Y.S. Kim2, Y.-H. Kim3, J.H. Cheon4, B.D. Ye5, J.S. Kim6

1Hanyang University Guri Hospital, Gastroenterology, Guri, Korea, Republic of, 2Inje University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 3Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 4Yonsei University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 5University of Ulsan College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 6Seoul National University College of Medicine, Internal Medicine, Seoul, Korea, Republic of

P150.

Responsiveness of endoscopic indices in the evaluation of ulcerative colitis

Authors:

B.G. Levesque1,2, E.V. Loftus3, R. Panaccione4, J.W. McDonald2, G. Van Assche5, G. Zou2, L. Stitt2, R. Khanna2, W.J. Sandborn1,2, G. D'Haens2,6, M.K. Vandervoort2, B.G. Feagan2,7, 1University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 2Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 3Mayo Clinic, Department of Internal Medicine, Rochester Minnesota, United States, 4University of Calgary, Division of Gastroenterology & Hepatology, Calgary Alberta, Canada, 5University Hospital of Gasthuisberg, Department of Gastroenterology, Leuven, Belgium, 6University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 7Western University, Department of Epidemiology and Biostatistics, Department of Medicine, London Ontario, Canada